Disease-level drug approval forecasting from trial-agnostic public data

Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before testing which drug-disease candidates are most likely to reach FDA approval could reduce development time and costs through early program advancement and disease prioritization. Yet existing approaches predict outcomes at a single level or stage or do not distinguish between disease outcomes for the same drug. We ask (1) whether FDA approval can be forecast for a drug-disease pair using only pre-clinical trial information, and (2) whether these forecasts can help prioritize diseases for the same drug. We built a coh...

<iframe src="https://silytics.si/embed/item/77c898cc-d8b3-4842-8f4f-eaa5b587139c" width="420" height="190" style="border:0" loading="lazy" title="Silytics entry"></iframe>

Silytics shows public metadata from arXiv and links to the original. Information may be incomplete or out of date. Last refreshed 17 October 2026. Licenses and terms of the original apply to the work itself. Not financial, legal or professional advice.